Skip to main content
Clinical Trials/NCT01903655
NCT01903655CompletedNot Applicable

Study of the Telomere-telomerase System and the Expression of Candidate Genes in the Leukocytes of Patients With Depressive Disorder: Search for Peripheral Markers of Somatic Stress

Centre Hospitalier Universitaire Dijon1 site in 1 country300 target enrollmentStarted: April 1, 2010Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
300
Locations
1
Primary Endpoint
Telomere length

Study Overview

Brief Summary

The mechanisms of oxidative stress and inflammation involved in mood disorders are factors of chronicity and severity. These mechanisms induce a phenomenon of accelerated cellular senescence and are reflected by alterations in systemic gene expression detectable in leukocytes in peripheral blood. The genetic markers of these mechanisms are clinically significant markers. The identification of new genetic markers will make it possible to improve evaluations of the severity and somatic consequences of depressive syndromes.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Persons who have given their written informed consent
  • absence of a diagnosis of major depressive disorder throughout the study and no history of psychiatric disorders
  • diagnosis of a first episode of a major depressive disorder
  • diagnosis of a recurrent major depressive disorder (at least three episodes) with or without resistance to therapy
  • the diagnosis of major depressive disorder with characteristics of melancholy must be clearly mentioned in the case report form but is not a reason for not being included in the study
  • the presence of a recent or older attempted suicide must lead to a careful clinical assessment of the diagnosis of depressive disorder and must be clearly mentioned in the case report form.

Exclusion Criteria

  • Persons not covered by the national Health Insurance Agency
  • Psychotic or bipolar disorders
  • Severe personality disorders
  • cardiovascular disease, proven inflammatory disease and cancer
  • persons unable to give their consent personally,
  • persons in emergency situations,
  • pregnant women,
  • breast-feeding women

Arms & Interventions

patients with recurrent depressive disorder

Other

a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)

Intervention: telomere length (Other)

control group

Other

patient with no depressive disorder during the study period and no psychiatric history

Intervention: telomere length (Other)

patients with a first episode of major depressive disorder

Other

a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features

Intervention: telomere length (Other)

Outcomes

Primary Outcomes

Telomere length

Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 months

Secondary Outcomes

  • level of oxidative stress.(participants will be followed for the duration of hospital stay, an expected average of 6 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials